New RNA Drug Offers Hope for Untreatable Adenoid Cystic Carcinoma

WATERTOWN, Mass. – April 21, 2026 – By Linda Coleman

In the relentless fight against cancer, some battlefields are more challenging than others. For patients with adenoid cystic carcinoma (ACC), a rare and aggressive cancer of the salivary glands, the front lines have been frustratingly static, with no approved systemic therapies and a prognosis that darkens with recurrence. Now, a new therapeutic approach is poised to enter the spotlight, offering a potential breakthrough by targeting the disease at its genetic roots.

Remix Therapeutics, a clinical-stage biotechnology company, announced today that pivotal results from its Phase 1 study of REM-422 will be featured in an oral presentation at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in June. REM-422 is a first-in-class oral medication designed to degrade the messenger RNA (mRNA) of MYB, a key oncogene that drives ACC. The upcoming presentation by Dr. Renata Ferrarotto of MD Anderson Cancer Center is highly anticipated, as it will unveil the first comprehensive look at the drug's safety and preliminary efficacy in a patient population with no other options.

A Decades-Long Stalemate

Adenoid cystic carcinoma is a slow-growing but highly invasive cancer. While initial treatment often involves surgery and radiation, the disease is notorious for its tendency to recur, often years later, and spread along nerves to distant sites. This relentless progression, combined with a lack of effective drugs, creates a dire situation for patients with recurrent or metastatic disease.

"For a disease like ACC, where we've been hitting a wall for decades, any new approach is welcome," commented one oncologist specializing in rare head and neck cancers, who is not involved with the study. "But a targeted therapy with a novel mechanism like this isn't just welcome; it's potentially revolutionary. We are watching these results very closely."

The challenge in treating ACC stems from its unique biology. Unlike many other cancers that respond to broad-acting chemotherapy or newer immunotherapies, ACC has remained stubbornly resistant. Past clinical trials with various kinase inhibitors and other agents have yielded disappointing results, leaving physicians to manage symptoms with treatments that offer only modest, temporary benefits. This therapeutic void underscores the urgent unmet medical need that Remix Therapeutics aims to fill.

Silencing the Cancer Driver

At the heart of REM-422's innovative design is its target: the MYB oncogene. In a majority of ACC tumors, a genetic flaw known as a translocation or overexpression leads to abnormally high levels of the MYB protein. This protein acts as a master switch, driving the uncontrolled cell growth, proliferation, and survival that characterize the cancer. For years, MYB was considered an "undruggable" target due to its structure and function as a transcription factor inside the cell nucleus.

Remix Therapeutics is circumventing this challenge by moving one step up the biological chain of command. Instead of trying to block the MYB protein, REM-422 targets the messenger RNA (mRNA) that carries the genetic instructions for making it. REM-422 is an oral small molecule that works by tricking the cell's machinery into inserting a "poison exon" into the MYB mRNA transcript. This alteration flags the mRNA for destruction through a natural cellular quality-control process called nonsense-mediated decay. The result is a dramatic reduction in MYB protein levels, effectively silencing the primary driver of the cancer.

This approach represents a paradigm shift, moving beyond traditional protein inhibitors to the burgeoning field of RNA modulation. If successful, it would not only provide a new weapon against ACC but also validate a powerful new modality for treating other MYB-driven cancers, such as acute myeloid leukemia (AML), for which REM-422 is also being studied.

A Strategically Paved Path to Clinic

The journey of a novel drug from the lab to patients is fraught with scientific and financial hurdles. Remix Therapeutics appears to be navigating this path with a clear strategy. The development of REM-422 has been accelerated by key regulatory advantages from the U.S. Food and Drug Administration (FDA), including Orphan Drug Designation for both ACC and AML, and, crucially, Fast Track designation for ACC.

Fast Track designation is designed to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. Its granting for REM-422 signals the FDA's recognition of the drug's potential to significantly impact the lives of ACC patients. This status, combined with the selection for an oral presentation at ASCO—an honor reserved for studies with potentially practice-changing implications—suggests the preliminary data is compelling.

The upcoming presentation will detail findings from the Phase 1 dose-escalation portion of the ARIA clinical trial. This phase is designed to determine the safest and most effective dose for further study. The data will provide the first clinical proof-of-concept for an oral MYB mRNA degrader in humans, a critical milestone for the company and the field of RNA therapeutics.

Building a Foundation for the Future

Supporting this ambitious clinical program is a company built on a solid financial and strategic foundation. Since its founding in 2018, Remix Therapeutics has raised over $200 million and, more notably, has inked major collaboration deals with pharmaceutical giants Janssen and Roche. These partnerships, worth potentially over $1 billion each in milestones, provide not only significant non-dilutive funding but also powerful validation of Remix's REMaster™ technology platform.

"The science is compelling, but the strategy is just as sharp," noted a biotech industry analyst. "Leveraging Orphan and Fast Track designations for a rare cancer is a classic biotech playbook for accelerating development and de-risking the path to market. The big pharma partnerships add another layer of validation and financial security."

This robust corporate backing ensures that Remix has the resources to advance REM-422 through the rigorous later stages of clinical testing and, if successful, toward commercialization. As the date for the ASCO meeting approaches, the oncology community, investors, and—most importantly—patients are waiting with anticipation. The data presented in Chicago could mark a turning point for a long-neglected disease and signal the arrival of a powerful new class of cancer therapies.